Osei Jeffery, Razavi Alexander C, Quyyumi Arshed A, Eapen Danny J, Sun Yan V, Khoury Muin J, Sperling Laurence
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Am J Prev Cardiol. 2025 Jun 1;22:101024. doi: 10.1016/j.ajpc.2025.101024. eCollection 2025 Jun.
Data on the prevalence and clinical characteristics of people with Familial hypercholesterolemia (FH) genetic variants across sex and diverse racial and ethnic groups in the United States are limited.
Using data from the research program, we examined the prevalence and clinical characteristics of FH variant carriers in a diverse U.S. population. and FH genetic variants were identified using the ClinVar database. Atherosclerotic cardiovascular disease (ASCVD) and lipid-lowering therapy (LLT) use were ascertained from electronic health records. Prevalence, ASCVD burden, and LLT use among FH variant carriers were estimated and stratified by sex, race, and ethnicity.
Among 245,388 participants (mean age 51.8 years, 59.3 % women, 51.3 % non-Hispanic White, 20.4 % non-Hispanic Black, 3 % non-Hispanic Asian, 19.3 % Hispanic), 448 were identified as FH genetic variant carriers, yielding a prevalence of 1 in 546 (95 % CI: 1/602- 1/500). Prevalence was highest among Asian non-Hispanics (1 in 286) and lowest in Hispanics (1 in 694); p-value = 0.003. Males had a higher prevalence of FH variants than females (1 in 485 vs. 1 in 602, p-value = 0.03). Regardless of LDL-C levels, FH variant carriers had a higher prevalence of ASCVD history than those without FH variants (p-value = 0.04). Black non-Hispanics, Asian non-Hispanics, and Hispanics had lower ASCVD prevalence and LLT use than White non-Hispanics. ASCVD prevalence was higher in males with FH variants than females (25 % vs. 18 %, p-value = 0.04).
Significant racial, ethnic, and sex disparities exist in the prevalence, ASCVD burden, and LLT use among FH variant carriers. Further targeted efforts, including increased genetic testing, are needed to improve FH detection and optimize treatment, particularly in racial and ethnic minority groups where LLT use remains inadequate.
在美国,关于家族性高胆固醇血症(FH)基因变异人群在性别以及不同种族和族裔群体中的患病率和临床特征的数据有限。
利用该研究项目的数据,我们在美国多样化人群中研究了FH变异携带者的患病率和临床特征。使用ClinVar数据库识别FH基因变异。从电子健康记录中确定动脉粥样硬化性心血管疾病(ASCVD)和降脂治疗(LLT)的使用情况。对FH变异携带者的患病率、ASCVD负担和LLT使用情况进行了估计,并按性别、种族和族裔进行分层。
在245,388名参与者中(平均年龄51.8岁,59.3%为女性,51.3%为非西班牙裔白人,20.4%为非西班牙裔黑人,3%为非西班牙裔亚洲人,19.3%为西班牙裔),448人被确定为FH基因变异携带者,患病率为1/546(95%CI:1/602 - 1/500)。患病率在非西班牙裔亚洲人中最高(1/286),在西班牙裔中最低(1/694);p值 = 0.003。男性FH变异的患病率高于女性(1/485对1/602,p值 = 0.03)。无论低密度脂蛋白胆固醇(LDL-C)水平如何,FH变异携带者有ASCVD病史的患病率高于无FH变异者(p值 = 0.04)。非西班牙裔黑人、非西班牙裔亚洲人和西班牙裔的ASCVD患病率和LLT使用率低于非西班牙裔白人。有FH变异的男性ASCVD患病率高于女性(25%对18%,p值 = 0.04)。
FH变异携带者在患病率、ASCVD负担和LLT使用方面存在显著的种族、族裔和性别差异。需要进一步开展有针对性的工作,包括增加基因检测,以改善FH的检测并优化治疗,特别是在LLT使用仍然不足的种族和族裔少数群体中。